70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in...
September 20, 2026
Share
70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups.